Company: SXTPW
Filing Date: 2025-03-27
Form Type: S-1/A
Source: 0001013762-25-003353
Chunk: 42

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: S-1/A
Chunk 42
---
      
 cleaning and safety protocols;                                                                   |

| ● | increased                                                                                      
 volatility or significant disruption of global financial markets due in part to any future     
 COVID-19 outbreak, which could have a negative impact on our ability to access capital markets 
 and other funding sources, on acceptable terms or at all and impede our ability to comply      
 with debt covenants; and                                                                       |

| ● | the                                                                                               
 further spread of COVID-19, and the requirements to take action to mitigate the spread of         
 any future COVID-19 outbreak (e.g., hygiene requirements or social distancing or other measures), 
 will impact our ability to carry out our business as usual and may materially adversely impact    
 global economic conditions, our business, results of operations, cash flows and financial         
 condition.                                                                                        |

To the extent COVID-19 or a similar public health threat has an impact on our business, it is likely to also have the effect of heightening many of the other risks described in this “ Risk Factors” section. U.S. public sector procurement of Arakoda might not materialize in the future, which could jeopardize our business. Sales to the U.S. DoD were important to our revenue stream in the recent past. Although, as of the date of this prospectus, we are not in discussions with the DoD about additional/future procurement, we anticipate that if certain conditions/events described in this paragraph occur, our sales to DoD could develop; however, there is no assurance that such conditions/events will occur. First, the position of Arakoda in the DoD formulary (Tricare, deployed personnel) needs to be improved from second/third tier to at least equivalency with competing products (as is the case for civilian use as recommended by the CDC). We believe that changes in pricing or reimbursement structure may be needed to secure that. Second, the shelf-life of the existing product requires extension, which is known to be technically possible as the shelf-life of Kodatef in Australia is 48 months, but appropriate data must be generated to meet FDA requirements. Finally, a change in the operational footprint of DoD deployments to areas with higher malaria attack rates (e.g., the Liberia deployment to manage the Ebola outbreak in 2014) may lead to a rapid reassessment by DoD of the position of Arakoda in the formulary (advancement of the last approved prophylactic antimalarial to co-equal standard of care took thirteen years). If none of these events transpire, we would not have